BOSTON (MarketWatch) -- Shares of Eli Lilly (US:lly) dipped 2% Tuesday in the wake of news that Johnson & Johnson (US:jnj), Pfizer Inc. (US:pfe) and Elan Corp. (US:eln) have pulled the plug on their jointly developed treatment for Alzheimer's disease due to poor clinical results. The compound, called bapineuzumab, was in Phase III testing. Lilly has a similar compound in late-stage development for Alzheimer's called solanezumab. The company is expected to unveil clinical results for solanezumab in the next few weeks. Analysts have been cautious about solanezumab's prospects, with some warning that the drug could turn out to be a flop.
No comments:
Post a Comment